Original Research Article

A study on serum bilirubin levels in coronary artery disease patients

N. Jayanthi1*, V. S. S. R. Abhilash Kasibhatla2, R. Shankar3

1Department of Medicine, 2Department of Preventive Medicine, VMKVMCH, Salem, Tamil Nadu, India
3Cardiology Resident, Care Hospital, Ram nagar, Visakhapatnam, Andhra Pradesh, India

Received: 03 September 2018
Revised: 22 September 2018
Accepted: 27 September 2018

*Correspondence:
Dr. N. Jayanthi,
E-mail: drjaya29@yahoo.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The protective effect of bilirubin relates to the antioxidant property of bilirubin, which prevents lipid oxidation, especially low-density lipoprotein (LDL), and inhibits free radical-induced dam-ages. Lower serum bilirubin level has been proven to be associated with endothelium and microvascular malfunction. The aim of the present study was to assess the association between serum bilirubin levels and coronary artery disease in comparison with controls without coronary artery disease.

Methods: A cross-sectional study was conducted for a period of a one year in our medical college hospital. Patients with evidence of coronary artery disease for not more than 10 years of duration confirmed by ECG, ECHO and other previous case records were taken as cases. Controls were selected matched with age, gender and other co-morbid conditions. Total of 200 subjects were included in the study with 100 cases and 100 controls. General and systemic examination was conducted on all study subjects including laboratory investigations like complete blood count, renal function test, lipid profile, viral markers such as HBsAG, HCVIgM and liver function test which includes total bilirubin, direct and indirect, liver enzymes, albumin and globulin levels. A 12 lead ECG and a transthoracic echocardiogram was performed for all patients.

Results: The various liver function test parameters were compared between the cases and controls it was found that the serum bilirubin levels which includes total bilirubin, direct bilirubin and indirect bilirubin was found to be lower among the case group compared to the control group and this difference was found to be statistically significant (p <0.05). A perfect linear correlation between the ejection fraction and serum bilirubin levels, as the ejection fraction decreases the serum bilirubin levels was also decreasing.

Conclusions: This study showed a significant association between the reduced serum bilirubin levels and the occurrence of CAD; therefore, bilirubin level can serve as a predictive factor, together with other influential factors for identifying a person at risk of developing coronary artery disease.

Keywords: Coronary artery disease, Ejection fraction, Risk factor, Serum bilirubin

INTRODUCTION

Coronary artery diseases (CAD) is still the major prevailing cause of mortality among advanced countries. On the other hand, the number of CAD victims is continuously increasing in developing countries.1 The remarkable prevalence of cardiovascular diseases in today’s society highlights the necessity of the identification of risk factors and screening of vulnerable individuals in using preventive and treatment methods.2 Although various main risk factors have been identified for atherosclerosis, including hypertension (HTN), hyperlipidemia, diabetes mellitus (DM), smoking, etc.,
for many years, the bile pigment bilirubin was considered to be only a toxic waste product formed during heme catabolism.\textsuperscript{3,4} Recent evidence, however, suggests that bilirubin acts as a potent physiologic antioxidant that may provide important protection against arteriosclerosis, coronary artery disease (CAD), and inflammation.\textsuperscript{9-11}

The antioxidant capacity of bilirubin and its potential ability to scavenge peroxyl radicals have led to the concept that mildly increased circulatory bilirubin may have a physiologic function to protect against disease processes that involve oxygen and peroxyl radicals.\textsuperscript{5} Indeed, inverse correlations between the presence of CAD and total bilirubin concentrations in the circulation were reported recently in several independent studies.\textsuperscript{5}

Additionally, plasma bilirubin correlates inversely with several established risk factors for CAD, including smoking, increased LDL-cholesterol, diabetes, and obesity, but is directly proportional to the protective factor HDL-cholesterol.\textsuperscript{12} The effect of bilirubin on the risk of cardiovascular disease is apparent in men but is less clear in women.\textsuperscript{33}

The protective effect of bilirubin relates to the antioxidant property of bilirubin, which prevents lipid oxidation, especially Low-density lipoprotein (LDL), and inhibits free radical-induced damages. Lower serum bilirubin level has been proven to be associated with endothelium and microvascular malfunction.\textsuperscript{14}

As of today, very few studies in India had been conducted to prove the association between serum bilirubin levels and coronary artery disease and so the present study was undertaken to assess the association between these two variables by comparing it with a control group.

The aim of the present study was to assess the association between serum bilirubin levels and coronary artery disease in comparison with controls without coronary artery disease.

**METHODS**

A cross-sectional study was conducted for a period of a one year in our medical college hospital. The study was started after getting the clearance from the institutional ethical committee.

Patients with evidence of coronary artery disease for not more than 10 years of duration confirmed by ECG, ECHO and other previous case records were taken as cases.

Patients with symptoms of congestive cardiac failure, chronic kidney disease, chronic liver disease, autoimmune diseases, COPD and malignancy were excluded from the study. Controls were selected matched with age, gender and other co-morbid conditions. Total of 200 subjects were included in the study with 100 cases and 100 controls. Informed consent was obtained from all the subjects involved in the study.

A complete socio-demographic details was obtained from all the subjects including the dietary habits and smoking/alcohol history. General and systemic examination was conducted on all study subjects including laboratory investigations like complete blood count, renal function test, lipid profile, viral markers such as HBsAG, HCVIgM and liver function test which includes total bilirubin, direct and indirect, liver enzymes, albumin and globulin levels. A 12 lead ECG and a transthoracic echocardiogram was performed for all patients.

Total serum bilirubin was measured in the laboratory by spectrophotometry method. In the Jendrassik-Grof allied methods, total bilirubin is reacted with diazotized sulfanilic acid in an acidic medium to form azobilirubin. The absorbance of the azo pigment is then measured as direct bilirubin and the total bilirubin is measured after treatment with alkaline tartrated solution, which shifts the maximum absorption of the azo pigment towards longer wavelength.

**Statistical analysis**

All the data were entered and analysed using SPSS version 22. Mean and standard deviation was derived for all the parametric variables and the parametric variables between the two groups (cases and controls) were compared using unpaired student T test and comparison between the frequencies was done by using chi-square test considering p <0.05 as statistically significant.

**RESULTS**

The entire study subjects were divided into two groups of 100 cases (with CVD) and 100 controls.

Table 1 shows the age and sex wise distribution of the study subjects. It is seen from the table that majority of the subjects were in the age group between 55 and 65 years. The minimum age was 42 and the maximum age was 73 years.

The mean age among the cases and controls group were between 63 and 65 years. The male subjects were more than the females with a male: female ratio of 2:1 among both the cases and controls. So, it shows that the cases and controls did not show any significant difference with respect to age and gender which implies that the controls were age and sex matched.

The most common risk factors for CVD like diabetes, hypertension, smoking, obesity and family history of CVD was found to be slightly higher among the cases than the control groups but it was not found to be statistically significant and it proves that the controls
were matched for almost all the risk factors for CVD except for dyslipidemia which was found to be significantly higher among the CVD patients than the controls (Table 2).

### Table 1: Age and sex wise distribution of the study subjects.

| Age group | Cases | Controls |
|-----------|-------|----------|
|           | Males | Females  | Males | Females |
| 40 - 45   | 4 (6%) | 1 (2.9%) | 5 (7%) | 0       |
| 46 - 50   | 7 (10.6%) | 1 (2.9%) | 8 (11.2%) | 2 (6.8%) |
| 51 - 55   | 3 (4.5%) | 2 (5.8%) | 3 (4.2%) | 2 (6.8%) |
| 56 - 60   | 21 (31.8%) | 6 (17.6%) | 23 (32.3%) | 9 (31%) |
| 61 - 65   | 16 (24.2%) | 15 (44.1%) | 14 (19.7%) | 12 (41.3%) |
| 66 - 70   | 10 (15.1%) | 5 (14.7%) | 9 (12.6%) | 3 (10.3%) |
| >70       | 5 (7.5%) | 4 (11.7%) | 9 (12.6%) | 2 (6.8%) |
| Total     | 66 (100%) | 34 (100%) | 71 (100%) | 29 (100%) |
| Mean±SD   | 63.8±7.9 | 64.6±8.1 | 62.3±8.4 | 63.7±8.6 |

### Table 2: Prevaling risk factors for CVD among study subjects.

| Risk factors          | Cases (n=100) | Controls (n=100) | P value |
|-----------------------|---------------|------------------|---------|
| Diabetes              | 33 (33%)      | 28 (28%)         | 0.318   |
| Hypertension          | 55 (55%)      | 43 (43%)         | 0.154   |
| Smoking               | 38 (38%)      | 35 (35%)         | 0.863   |
| Family history of CVD | 41 (41%)      | 32 (32%)         | 0.281   |
| Obesity               | 27 (27%)      | 19 (19%)         | 0.182   |
| Dyslipidemia          | 63 (63%)      | 42 (42%)         | 0.003   |

### Table 3: Distribution of the cases based on their duration of CVD.

| Duration of CVD | Frequency | Percentage | Mean±SD |
|-----------------|-----------|------------|---------|
| <3 years        | 21        | 21%        | 4.2±2.6 |
| 3 - 5 years     | 48        | 48%        |         |
| 5 - 7 years     | 22        | 22%        |         |
| >7 years        | 9         | 9%         |         |
| Total           | 100       | 100%       |         |

The duration of CVD among the cases varied from 2 years to 9 years with majority of the subjects’ duration was between 3 and 5 years and the mean duration was 4.2 years. The patients’ CVD status was confirmed by history, ECG findings and ECHO reports (Table 3).

The various liver function test parameters were compared between the cases and controls it was found that the serum bilirubin levels which includes total bilirubin, direct bilirubin and indirect bilirubin was found to be lower among the case group compared to the control group and this difference was found to be statistically significant, whereas the other parameters like SGOT, SGPT and GGT levels did not show much difference between the case and control groups and the difference in values were not statistically significant (Table 4).

### Table 4: Comparison of the liver function test parameters between the CVD patients and the controls.

| LFT               | Cases (mean±SD) | Controls (mean±SD) | P value |
|-------------------|-----------------|--------------------|---------|
| Total bilirubin   | 0.89±0.07       | 1.23±0.21          | <0.001  |
| Direct bilirubin  | 0.23±0.04       | 0.48±0.08          | <0.001  |
| Indirect bilirubin| 0.64±0.09       | 0.82±0.11          | <0.001  |
| SGOT (IU/L)       | 25              | 28                 | 0.571   |
| SGPT (IU/L)       | 29              | 33                 | 0.219   |
| GGT (IU/L)        | 31              | 29                 | 0.313   |

p value derived by applying student T test

For all the CVD patients an echocardiogram was performed and their ejection fraction was recorded and it was correlated with the serum bilirubin levels, authors found a perfect linear correlation between the ejection fraction and serum bilirubin levels, as the ejection fraction decreases the serum bilirubin levels was also decreasing and all the serum bilirubin parameters were found to be very low in patients with ejection fraction <50% when compared to patients with ejection fraction >60% and this association was found to be statistically significant (p <0.05) (Table 5).

**DISCUSSION**

Atherosclerosis is considered to be the most common underlying cause for the coronary artery disease (CAD), which is the major cause of mortality worldwide both in

---

**REFERENCES**

Jayanthi N et al. Int J Adv Med. 2018 Dec;5(6):1437-1442

---

**DATA**

| Table 4: Comparison of the liver function test parameters between the CVD patients and the controls. | CVD | Controls | P value |
|---|---|---|---|
| Total bilirubin | 0.89±0.07 | 1.23±0.21 | <0.001 |
| Direct bilirubin | 0.23±0.04 | 0.48±0.08 | <0.001 |
| Indirect bilirubin | 0.64±0.09 | 0.82±0.11 | <0.001 |
| SGOT (IU/L) | 25 | 28 | 0.571 |
| SGPT (IU/L) | 29 | 33 | 0.219 |
| GGT (IU/L) | 31 | 29 | 0.313 |
developed and developing countries.\textsuperscript{15} Whereas on the other hand antioxidants are the predominant adaptive responses by the arterial vasculature in response to the oxidative stress thereby preventing the atherosclerosis.\textsuperscript{3} Bilirubin, being a toxic waste product formed during heme catabolism is in fact a potent physiological antioxidant that provides important protection against atherosclerosis and inflammation.\textsuperscript{16}

A particular enzyme namely the heme oxygenase (HO) is a stress inducible enzyme in the heme catabolism which plays an important role in cell defense mechanism against oxidative injury.

The products of the catabolic reaction, i.e. bilirubin, carbon monoxide and iron have a protective role. The other important role of bilirubin, the natural antioxidants are the inhibition of vascular cell adhesion molecule VCAM-1 preventing the proliferation of the smooth muscle cells and the transendothelial migration of the leucocytes.\textsuperscript{17}

### Table 5: Association and correlation between serum bilirubin levels and the ejection fraction among the CVD patients.

| Serum bilirubin                  | >60 % (n=28) | 50-60 % (n=51) | <50 % (n=21) | P value | r value |
|---------------------------------|-------------|---------------|-------------|---------|---------|
| Total bilirubin (mean±SD)       | 1.1±0.32    | 0.84±0.23     | 0.73±0.18   | <0.001  | 0.915   |
| Direct bilirubin (mean±SD)      | 0.41±0.10   | 0.32±0.08     | 0.21±0.07   | <0.001  | 0.899   |
| Indirect bilirubin (mean±SD)    | 0.72±0.24   | 0.66±0.09     | 0.60±0.05   | <0.001  | 0.934   |

Plasma bilirubin inversely correlated with risk factors of CAD- smoking, diabetes and obesity, thus emphasizing the oxidative stress underlying in them; but in present study authors did not observed such correlation as authors matched most of the risk factors between the cases and controls. Inverse relationship between the presence of CAD and circulatory total bilirubin was first observed by Schwertner et al.\textsuperscript{5}

Male gender is one of the most important risk factors for CAD. The same was found in our study. Males were predominant in cases and so we matched the controls accordingly. Authors also matched the cases and controls with regards to age and other comorbidities thereby removing the confounding factors responsible for the lowering of bilirubin as a result of the oxidative stress and other mechanisms.\textsuperscript{18}

Present study found a significant inverse association between serum bilirubin and CAD in comparison with control, bilirubin levels found to be significantly lower in CAD patients in comparison with the controls (p <0.001) and a similar type of results was also quoted by Taban SM et al, and in their study they had also found a significant association between the bilirubin levels and the severity of CAD by doing an angiogram.\textsuperscript{19} So it seems that higher bilirubin level has a protective effect against coronary artery stenosis (CAS).

The present study among 100 CAD patients and 100 healthy controls confirmed the results of several previous epidemiological studies that low serum bilirubin levels were associated with increased risk for coronary events.\textsuperscript{7,20,21} A recent study in patients with peripheral arterial disease (PAD) revealed similar results showing a clear association between low bilirubin concentrations and PAD.\textsuperscript{22}

Present study showed a higher level of mean total bilirubin in males in comparison to females, but the difference was not statistically significant, however lower levels of bilirubin in females may be attributed to the influence of estrogens. This may relate to the increased secretion of bilirubin through the induction of UDP-glucuronil transferase enzyme in liver. Estrogens also decrease LDL level, increase HDL level and reduce LDL oxidation.\textsuperscript{23} Recently, low serum bilirubin levels have been proposed as a useful biomarker to predict cardiovascular risk and suggests that bilirubin acts as a potent physiologic antioxidant and anti-inflammatory agent. Studies have shown that elevated serum bilirubin concentrations provide important protection against atherosclerotic diseases.\textsuperscript{3} Several authors have suggested that bilirubin plays a potential role in inhibition of lipid oxidation.\textsuperscript{24} An inverse correlation between the presence of coronary artery disease, peripheral arterial disease, carotid intima-media thickness and bilirubin has been reported in several studies. Subnormal levels of plasma bilirubin are associated with premature coronary artery disease and cardiovascular morbidity.\textsuperscript{25} In a previous study, the 3-year incidence of coronary artery disease was significantly lower in patients with Gilbert syndrome.\textsuperscript{26}

This study showed a significant relation between ejection fraction with total serum bilirubin the ejection fraction showed a descending trend as serum bilirubin level decreased and a similar type of results was also quoted by Taban SM et al.\textsuperscript{19}

One of the major limitations of this study is it was not conducted in a prospective manner to exactly identify the causal association between bilirubin levels and CAD, it was only a cross-sectional design and secondly, authors didn’t associate the severity of CAD with bilirubin levels by doing an angiogram study.
CONCLUSION

This study showed a significant association between the reduced serum bilirubin levels and the occurrence of CAD; therefore, bilirubin level can serve as a predictive factor, together with other influential factors for identifying a person at risk of developing coronary artery disease. Further studies with a larger sample and a prospective design would throw more light on bilirubin being considered as an independent risk factor for coronary artery disease.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. Mech Dis. 2006 Feb 28;1:297-329.
2. Louise D. Bilirubin protects against heart disease. Medical Xpress. 2012.
3. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem. 2000 Nov 1;46(11):1723-7.
4. Muraca M, Favery J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. Gastroenterol. 1984 Aug 1;87(2):308-13.
5. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994 Jan 1;40(1):18-23.
6. Movahed A, Iranpour D, Nabiour I, Jafari M, Akbarzadeh S, Assadi M, et al. Plasma malondialdehyde, bilirubin, homocysteine and total antioxidant capacity in patients with angiographically defined coronary artery disease. African J Biotechnol. 2012;11(13):3187-91.
7. Troughton JA, Woodside JV, Young IS, Arveiler D, Amouyal P, Ferrières J, et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prevent Rehabilitation. 2007 Feb;14(1):79-84.
8. Rigato I, Ostrow JD, Tilibelli C. Bilirubin and the risk of common non-hepatic diseases. Trends Molecular Med. 2005 Jun 1;11(6):277-83.
9. Yamaguchi T, Terakado M, Horio F, Aoki K, Tanaka M, Nakajima H. Role of bilirubin as an antioxidant in an ischemia–reperfusion of rat liver and induction of heme oxygenase. Biochem Biophysical Res Communications. 1996 Jun 5;223(1):129-35.
10. Siow RC, Sato H, Mann GE. Heme oxygenase–carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide?. Cardiovasc Res. 1999 Feb 1;41(2):385-94.
11. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987 Feb 27;235(4792):1043-6.
12. Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis. 1997 May;1:131(1):107-13.
13. Hunt SC, Kronenberg F, Eckfeldt JH, Hopkins PN, Myers RH, Heiss G. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis. 2001 Feb 15;154(3):747-54.
14. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, ET AL. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis. 2006 Feb 1;184(2):437-7.
15. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, et al. Heart disease and stroke statistics-2013 update: a report from the American heart association. Circulation. 2013 Jan 1;127(1):e-e245.
16. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(9):1786-95.
17. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alphatocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Bio Chem. 1994;269(24):16712-9.
18. Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J. 2010;51(2):86-91.
19. Taban SM, Golmohammadi A, Parvizi R, Kezerlou AN, Sepahram A, Hosnavi Z. The relation of serum bilirubin level with coronary artery disease based on angiographic findings. Crescent J Med Biol Sci. 2015;2(4):130-4.
20. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003 May;228(5):568-71.
21. Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (the framingham offspring study). Am J Cardiol. 2003;91(4A):485-8.
22. Rantner B, Kollerits B, Anderwald-Stadler M, Klein-Weigel P, Gruber I, Gehringer A, et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from...
the CAVASIC study. Clin Chem. 2008 May 1;54(5):851-7.

23. Freeman R. Hormone replacement therapy (estrogen and progesterone): is it necessary for heart disease prevention?. Preventive Cardiol. 2000 Jan;3(1):21-4.

24. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proceed National Academy Sci. 1987 Aug 1;84(16):5918-22.

25. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke. 2001 Feb 1;32(2):580-3.

26. Vítek L, Jirsa Jr M, Brodanová M, Kaláb M, Mareček Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002 Feb 1;160(2):449-56.

Cite this article as: Jayanthi N, Kasibhatla AVSSR, Shankar R. A study on serum bilirubin levels in coronary artery disease patients. Int J Adv Med 2018;5:1437-42.